You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
PARP Inhibition for Gliomas (PI-4G or π4g)
Not yet recruiting
  • Recurrent Glioblastoma
  • +3 more
  • Oklahoma City, Oklahoma
    Stephenson Cancer Center
2022-03-25
Mar 25, 2022
C
Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
Not yet recruiting
  • Recurrent Anaplastic Astrocytoma
  • +7 more
  • Neural Stem Cells-expressing CRAd-S-pk7
  • Resection
  • Duarte, California
    City of Hope Medical Center
2022-02-16
Feb 16, 2022
D
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Active, not recruiting
  • Recurrent Gynecological Cancer
  • +10 more
  • Boston, Massachusetts
    Martin King
2022-03-02
Mar 2, 2022
A
Association Between Plasma Level of Mannose Binding Lectin and Human Reproduction
Recruiting
  • Mannose-Binding Lectin Deficiency
  • +6 more
    • Aarhus, Denmark
      Aagaard Klinik
    2022-02-02
    Feb 2, 2022
    S
    Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
    Active, not recruiting
    • Recurrent Solid Tumor
    • +21 more
    • Palo Alto, California
    • +8 more
    2021-12-13
    Dec 13, 2021
    N
    Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
    Recruiting
    • Recurrent Endometrial Adenocarcinoma
    • +7 more
    • Ipilimumab
    • Nivolumab
    • Philadelphia, Pennsylvania
    • +1 more
    2022-04-07
    Apr 7, 2022
    N
    Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
    Not yet recruiting
    • Recurrent Angioimmunoblastic T-Cell Lymphoma
    • +13 more
    • Brentuximab Vedotin
    • Pembrolizumab
    • Chicago, Illinois
      Northwestern University
    2022-01-24
    Jan 24, 2022
    P
    131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
    Recruiting
    • Recurrent Medulloblastoma
    • Recurrent Ependymoma
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    2022-04-07
    Apr 7, 2022
    B
    Study of Recombinant Human Endostatin Combined With Temozolomide and Irinotecan in Recurrent Gliomas
    Recruiting
    • Glioblastoma, Recurrent
    • Lower Grade Glioma, Recurrent
    • recombinant human endostatin,temozolomide,irinotecan
    • Beijing, China
      Beijing Sanbo Brain Hospital
    2022-02-10
    Feb 10, 2022
    J
    Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
    Recruiting
    • Recurrent Endometrial Carcinoma
    • +3 more
    • Los Angeles, California
      UCLA / Jonsson Comprehensive Cancer Center
    2021-10-28
    Oct 28, 2021
    C
    Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
    Recruiting
    • Recurrent Anaplastic Astrocytoma
    • +6 more
    • Carboxylesterase-expressing Allogeneic Neural Stem Cells
    • +4 more
    • Duarte, California
      City of Hope Medical Center
    2022-02-17
    Feb 17, 2022
    U
    Role of Repeat Resection in Recurrent Glioblastoma
    Recruiting
    • Recurrent Glioblastoma
    • Glioblastoma - Category
    • Repeat Surgical Management of Recurrent GBM
    • Edmonton, Alberta, Canada
      University of Alberta Division of Neurosurgery
    2022-04-05
    Apr 5, 2022
    M
    Platelet Indices and Recurrent Pregnancy Loss - 2021
    Completed
    • Abortion, Recurrent
    • platelet indices
    • Shibīn Al Kawm, Menoufia, Egypt
      Menoufia University hospital
    2021-12-29
    Dec 29, 2021
    M
    REMASTer: REcurrent Brain Metastases After SRS Trial
    Not yet recruiting
    • Brain Metastases
    • +3 more
    • Radiation Therapy
    • +2 more
    • (no location specified)
    2021-11-16
    Nov 16, 2021
    M
    Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Recruiting
    • Recurrent Fallopian Tube Clear Cell Adenocarcinoma
    • +5 more
    • Etigilimab
    • Nivolumab
    • Houston, Texas
      M D Anderson Cancer Center
    2021-11-22
    Nov 22, 2021
    O
    Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
    Active, not recruiting
    • BRCA1 Gene Mutation
    • +9 more
    • Laboratory Biomarker Analysis
    • +3 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    2022-04-05
    Apr 5, 2022
    M
    Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
    Not yet recruiting
    • Recurrent Glioblastoma
    • Recurrent Gliosarcoma
    • Houston, Texas
      M D Anderson Cancer Center
    2022-03-31
    Mar 31, 2022
    G
    PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
    Recruiting
    • Recurrent Medulloblastoma
    • +2 more
    • Durham, North Carolina
      Duke University Medical Center
    2022-01-08
    Jan 8, 2022
    Z
    Methylene Blue Spray for Identification of Recurrent Laryngeal Nerve and Parathyroid Gland - 2021
    Completed
    • Methylene Blue
    • +2 more
    • methylene blue identification
    • Zagazig, Egypt
      Zagazig university hospitals
    2021-10-28
    Oct 28, 2021
    C
    Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
    Recruiting
    • Recurrent Glioblastoma
    • +3 more
    • Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)
    • Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)
    • Duarte, California
      City of Hope Medical Center
    2022-02-25
    Feb 25, 2022
    M
    Pembrolizumab in Treating Patients With Recurrent Glioblastoma
    Active, not recruiting
    • Recurrent Glioblastoma
    • Recurrent Gliosarcoma
    • Laboratory Biomarker Analysis
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    2022-02-03
    Feb 3, 2022
    N
    Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
    Not yet recruiting
    • Platinum-Refractory Fallopian Tube Carcinoma
    • +11 more
    • Copanlisib Hydrochloride
    • +4 more
    • (no location specified)
    2022-04-05
    Apr 5, 2022
    C
    Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
    Recruiting
    • Recurrent Glioblastoma
    • Cleveland, Ohio
      Cleveland Clinic Taussig Cancer institute, Case Comprehensive Ca
    2022-03-11
    Mar 11, 2022
    R
    Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
    Not yet recruiting
    • Ovarian Clear Cell Adenocarcinoma
    • +14 more
    • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
    • +4 more
    • Buffalo, New York
    • +1 more
    2022-04-04
    Apr 4, 2022
    B
    Apatinib in the Treatment of Recurrent Atypical/Malignant Meningioma in Adults
    Recruiting
    • Recurrent Atypical/Malignant Meningioma
    • Apatinib Mesylate
    • Beijing, Beijing, China
      Sanbo Brain Hospital
    2022-02-10
    Feb 10, 2022